201 related articles for article (PubMed ID: 19770179)
1. Improving the pharmacokinetics/pharmacodynamics of prolactin, GH, and their antagonists by fusion to a synthetic albumin-binding peptide.
Langenheim JF; Chen WY
J Endocrinol; 2009 Dec; 203(3):375-87. PubMed ID: 19770179
[TBL] [Abstract][Full Text] [Related]
2. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation.
Llovera M; Pichard C; Bernichtein S; Jeay S; Touraine P; Kelly PA; Goffin V
Oncogene; 2000 Sep; 19(41):4695-705. PubMed ID: 11032019
[TBL] [Abstract][Full Text] [Related]
3. Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists.
Langenheim JF; Tan D; Walker AM; Chen WY
Mol Endocrinol; 2006 Mar; 20(3):661-74. PubMed ID: 16269515
[TBL] [Abstract][Full Text] [Related]
4. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
Beck MT; Chen NY; Franek KJ; Chen WY
Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
[TBL] [Abstract][Full Text] [Related]
5. The role of human prolactin and its antagonist, G129R, in mammary gland development and DMBA-initiated tumorigenesis in transgenic mice.
Tomblyn S; Langenheim JF; Jacquemart IC; Holle E; Chen WY
Int J Oncol; 2005 Nov; 27(5):1381-9. PubMed ID: 16211235
[TBL] [Abstract][Full Text] [Related]
6. A novel design of targeted endocrine and cytokine therapy for breast cancer.
Zhang G; Li W; Holle L; Chen N; Chen WY
Clin Cancer Res; 2002 Apr; 8(4):1196-205. PubMed ID: 11948133
[TBL] [Abstract][Full Text] [Related]
7. Mode of the autocrine/paracrine mechanism of growth hormone action.
Liu N; Mertani HC; Norstedt G; Törnell J; Lobie PE
Exp Cell Res; 1997 Nov; 237(1):196-206. PubMed ID: 9417883
[TBL] [Abstract][Full Text] [Related]
8. A major prolactin-binding complex on human milk fat globule membranes contains cyclophilins A and B: the complex is not the prolactin receptor.
Lorenson MY; Ueda EK; Chen KE; Walker AM
Am J Physiol Endocrinol Metab; 2012 Mar; 302(5):E585-94. PubMed ID: 22205628
[TBL] [Abstract][Full Text] [Related]
9. Different elements of mini-helix 1 are required for human growth hormone or prolactin action via the prolactin receptor.
Peterson FC; Brooks CL
Protein Eng Des Sel; 2004 May; 17(5):417-24. PubMed ID: 15252206
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells.
Cataldo L; Chen NY; Yuan Q; Li W; Ramamoorthy P; Wagner TE; Sticca RP; Chen WY
Int J Oncol; 2000 Dec; 17(6):1179-85. PubMed ID: 11078803
[TBL] [Abstract][Full Text] [Related]
11. Alteration of cell shape, adhesion, and lipid accumulation in human breast cancer cells (T-47D) by human prolactin and growth hormone.
Shiu RP; Paterson JA
Cancer Res; 1984 Mar; 44(3):1178-86. PubMed ID: 6692402
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel ligand that activates JAK2/STAT5 signaling through a heterodimer of prolactin receptor and growth hormone receptor.
Langenheim JF; Chen WY
J Recept Signal Transduct Res; 2009; 29(2):107-12. PubMed ID: 19519175
[TBL] [Abstract][Full Text] [Related]
13. Equivalent potency and pharmacokinetics of recombinant human growth hormones with or without an N-terminal methionine.
Moore JA; Rudman CG; MacLachlan NJ; Fuller GB; Burnett B; Frane JW
Endocrinology; 1988 Jun; 122(6):2920-6. PubMed ID: 3371267
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of lactosaminated recombinant human growth hormone in mice.
Li YC; Guan CT; Zhao KQ; Chen ZL; Li TL
Acta Pharmacol Sin; 2001 May; 22(5):450-4. PubMed ID: 11743895
[TBL] [Abstract][Full Text] [Related]
15. Tumor expression of human growth hormone and human prolactin predict a worse survival outcome in patients with mammary or endometrial carcinoma.
Wu ZS; Yang K; Wan Y; Qian PX; Perry JK; Chiesa J; Mertani HC; Zhu T; Lobie PE
J Clin Endocrinol Metab; 2011 Oct; 96(10):E1619-29. PubMed ID: 21849525
[TBL] [Abstract][Full Text] [Related]
16. In Vitro and in Vivo Characterization of MOD-4023, a Long-Acting Carboxy-Terminal Peptide (CTP)-Modified Human Growth Hormone.
Hershkovitz O; Bar-Ilan A; Guy R; Felikman Y; Moschcovich L; Hwa V; Rosenfeld RG; Fima E; Hart G
Mol Pharm; 2016 Feb; 13(2):631-9. PubMed ID: 26713839
[TBL] [Abstract][Full Text] [Related]
17. Physico-chemical and biological characterizations of two human prolactin analogs exhibiting controversial bioactivity, synthesized in Chinese hamster ovary (CHO) cells.
Soares CR; Glezer A; Okazaki K; Ueda EK; Heller SR; Walker AM; Goffin V; Bartolini P
Protein Expr Purif; 2006 Aug; 48(2):182-94. PubMed ID: 16814566
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics analysis of sustained release hGH biodegradable implantable tablets using a mouse model of human ovarian cancer.
Santoveña A; Fariña JB; Llabrés M; Zhu Y; Dannies P
Int J Pharm; 2010 Mar; 388(1-2):175-80. PubMed ID: 20060456
[TBL] [Abstract][Full Text] [Related]
19. Human growth hormone and human prolactin function as autocrine/paracrine promoters of progression of hepatocellular carcinoma.
Kong X; Wu W; Yuan Y; Pandey V; Wu Z; Lu X; Zhang W; Chen Y; Wu M; Zhang M; Li G; Tan S; Qian P; Perry JK; Lobie PE; Zhu T
Oncotarget; 2016 May; 7(20):29465-79. PubMed ID: 27102295
[TBL] [Abstract][Full Text] [Related]
20. A growth hormone/prolactin-binding protein in human milk.
Mercado M; Baumann G
J Clin Endocrinol Metab; 1994 Dec; 79(6):1637-41. PubMed ID: 7989468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
